Robert M. Lorence

4.5k total citations · 1 hit paper
51 papers, 3.7k citations indexed

About

Robert M. Lorence is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Robert M. Lorence has authored 51 papers receiving a total of 3.7k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Pulmonary and Respiratory Medicine, 18 papers in Oncology and 17 papers in Molecular Biology. Recurrent topics in Robert M. Lorence's work include Lung Cancer Treatments and Mutations (18 papers), Virus-based gene therapy research (16 papers) and Photosynthetic Processes and Mechanisms (10 papers). Robert M. Lorence is often cited by papers focused on Lung Cancer Treatments and Mutations (18 papers), Virus-based gene therapy research (16 papers) and Photosynthetic Processes and Mechanisms (10 papers). Robert M. Lorence collaborates with scholars based in United States, Taiwan and Canada. Robert M. Lorence's co-authors include Robert B. Gennis, Robert Walter, James Chih‐Hsin Yang, Kirk W. Reichard, Mark E. Peeples, Keith W. Kelley, Wu‐Chou Su, Mehdi Shahidi, Xiuyu Julie Cong and William S. Groene and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Journal of Clinical Oncology.

In The Last Decade

Robert M. Lorence

49 papers receiving 3.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial

2012 776 citations Vincent A. Miller, Vera Hirsh et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Robert M. Lorence United States	29	1.7k	1.5k	1.4k	1.3k	507	51	3.7k
Thomas Y. Shih United States	37	1.4k 0.9×	3.9k 2.6×	118 0.1×	1.6k 1.2×	215 0.4×	61	5.1k
Grazyna Kochan Spain	34	1.6k 0.9×	1.3k 0.8×	293 0.2×	148 0.1×	278 0.5×	94	3.5k
Nobuo Horikoshi United States	29	1.0k 0.6×	2.6k 1.8×	171 0.1×	681 0.5×	269 0.5×	62	3.4k
Yanhui Xu China	39	522 0.3×	4.1k 2.8×	111 0.1×	423 0.3×	358 0.7×	104	5.6k
Clifford D. Mol United States	26	1.1k 0.7×	5.0k 3.3×	195 0.1×	642 0.5×	233 0.5×	31	6.3k
Jeffrey P. Bond United States	31	590 0.4×	2.0k 1.4×	212 0.2×	528 0.4×	176 0.3×	71	3.2k
Joseph L. Kim United States	14	697 0.4×	2.9k 2.0×	319 0.2×	302 0.2×	317 0.6×	21	3.9k
Inger Helene Madshus Norway	34	845 0.5×	2.8k 1.9×	197 0.1×	261 0.2×	254 0.5×	67	4.3k
Lawrence Weissbach United States	21	746 0.4×	1.7k 1.1×	211 0.2×	451 0.3×	122 0.2×	34	2.6k
Dana M. Fowlkes United States	24	515 0.3×	2.3k 1.5×	143 0.1×	1.4k 1.1×	151 0.3×	35	3.4k

Countries citing papers authored by Robert M. Lorence

Since Specialization

Citations

This map shows the geographic impact of Robert M. Lorence's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert M. Lorence with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert M. Lorence more than expected).

Fields of papers citing papers by Robert M. Lorence

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert M. Lorence. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert M. Lorence. The network helps show where Robert M. Lorence may publish in the future.

Co-authorship network of co-authors of Robert M. Lorence

This figure shows the co-authorship network connecting the top 25 collaborators of Robert M. Lorence. A scholar is included among the top collaborators of Robert M. Lorence based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert M. Lorence. Robert M. Lorence is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Reck, Martin, K. Syrigos, Skaidrius Miliauskas, et al.. (2024). A non-interventional biomarker study in patients with adenocarcinoma of the lung treated with nintedanib plus docetaxel following progression on chemotherapy and/or immunotherapy: LUME-BioNIS. Translational Lung Cancer Research. 13(12). 3364–3381.

Geoerger, Birgit, Lynley V. Marshall, Karsten Nysom, et al.. (2023). Afatinib in paediatric patients with recurrent/refractory ErbB-dysregulated tumours: Results of a phase I/expansion trial. European Journal of Cancer. 188. 8–19. 3 indexed citations

Westeel, Virginie, Wolfgang Schuette, T. Urban, et al.. (2023). Safety and tolerability of weekly docetaxel plus nintedanib: A phase I trial after first-line chemotherapy failure in NSCLC. PLoS ONE. 18(10). e0292307–e0292307.

Levy, Benjamin, Fabrice Barlési, Luis Paz‐Ares, et al.. (2022). Phase II study of afatinib plus pembrolizumab in patients with squamous cell carcinoma of the lung following progression during or after first-line chemotherapy (LUX-Lung-IO). Lung Cancer. 166. 107–113. 6 indexed citations

Chang, Gee‐Chen, Chun‐Ming Tsai, Jin‐Yuan Shih, et al.. (2018). P1.01-11 Named Patient Use Program for Afatinib in Advanced NSCLC with Progression on Prior Therapy: Experience from Asian Centers. Journal of Thoracic Oncology. 13(10). S463–S463. 2 indexed citations

Ewer, Michael S., et al.. (2015). Cardiac safety of afatinib: a review of data from clinical trials. Cardio-Oncology. 1(1). 3–3. 24 indexed citations

Hirsh, Vera, J. Cadranel, Xiuyu Julie Cong, et al.. (2013). Symptom and Quality of Life Benefit of Afatinib in Advanced Non–Small-Cell Lung Cancer Patients Previously Treated with Erlotinib or Gefitinib: Results of a Randomized Phase IIb/III Trial (LUX-Lung 1). Journal of Thoracic Oncology. 8(2). 229–237. 61 indexed citations

Miller, Vincent A., Vera Hirsh, Jacques Cadranel, et al.. (2012). Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. The Lancet Oncology. 13(5). 528–538. 776 indexed citations breakdown →

Yang, James Chih‐Hsin, Jin‐Yuan Shih, Wu‐Chou Su, et al.. (2012). Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial. The Lancet Oncology. 13(5). 539–548. 332 indexed citations

10.

Lorence, Robert M., M. Scot Roberts, James P. O’Neil, et al.. (2007). Phase 1 Clinical Experience Using Intravenous Administration of PV701, an Oncolytic Newcastle Disease Virus. Current Cancer Drug Targets. 7(2). 157–167. 93 indexed citations

11.

Hotte, Sébastien J., Robert M. Lorence, Hal W. Hirte, et al.. (2007). An Optimized Clinical Regimen for the Oncolytic Virus PV701. Clinical Cancer Research. 13(3). 977–985. 98 indexed citations

12.

Laurie, Scott A., John C. Bell, Harold Atkins, et al.. (2006). A Phase 1 Clinical Study of Intravenous Administration of PV701, an Oncolytic Virus, Using Two-Step Desensitization. Clinical Cancer Research. 12(8). 2555–2562. 103 indexed citations

13.

Lorence, Robert M., Kirk W. Reichard, Hernan M. Reyes, et al.. (1994). Complete Regression of Human Neuroblastoma Xenografts in Athymic Mice After Local Newcastle Disease Virus Therapy. JNCI Journal of the National Cancer Institute. 86(16). 1228–1233. 102 indexed citations

14.

Reichard, Kirk W., et al.. (1993). Retinoic acid enhances killing of neuroblastoma cells by Newcastle disease virus. Journal of Pediatric Surgery. 28(10). 1221–1226. 11 indexed citations

15.

Reichard, Kirk W., Robert M. Lorence, Mark E. Peeples, et al.. (1992). Newcastle disease virus selectively kills human tumor cells. Journal of Surgical Research. 52(5). 448–453. 199 indexed citations

16.

Edwards, Carl K., Robert M. Lorence, Diane Dunham, et al.. (1991). Hypophysectomy Inhibits the Synthesis of Tumor Necrosis Factor α by Rat Macrophages: Partial Restoration by Exogenous Growth Hormone or Interferon γ*. Endocrinology. 128(2). 989–996. 73 indexed citations

17.

Lorence, Robert M., et al.. (1990). REPORTS: Serum Protease Inhibitor Abrogation of Newcastle Disease Virus Enhancement of Cytolysis by Recombinant Tumor Necrosis Factors Alpha and Beta. JNCI Journal of the National Cancer Institute. 82(3). 213–217. 13 indexed citations

18.

Lorence, Robert M., et al.. (1988). Newcastle Disease Virus as an Antineoplastic Agent: Induction of Tumor Necrosis Factor- and Augmentation of Its Cytotoxicity2. JNCI Journal of the National Cancer Institute. 80(16). 1305–1312. 125 indexed citations

19.

Lorence, Robert M., John G. Koland, & Robert B. Gennis. (1986). Coulometric and spectroscopic analysis of the purified cytochrome d complex of Escherichia coli: evidence for the identification of "cytochrome a1" as cytochrome b595. Biochemistry. 25(9). 2314–2321. 95 indexed citations

20.

Fee, J.A., Miles G. Choc, Karen L. Findling, Robert M. Lorence, & Takamasa Yoshida. (1980). Properties of a copper-containing cytochrome c1aa3 complex: a terminal oxidase of the extreme thermophile Thermus thermophilus HB8.. Proceedings of the National Academy of Sciences. 77(1). 147–151. 79 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact